Synthesis and biological evaluation of potential acetylcholinesterase inhibitors based on a benzoxazine core

Arch Pharm (Weinheim). 2018 May;351(5):e1800024. doi: 10.1002/ardp.201800024. Epub 2018 Apr 3.

Abstract

With the purpose of expanding the structural variety of chemical compounds available as pharmacological tools for the treatment of Alzheimer's disease, we synthesized and evaluated a novel series of indole-benzoxazinones (Family I) and benzoxazine-arylpiperazine derivatives (Family II) for potential human acetylcholinesterase (hAChE) inhibitory properties. The most active compounds 7a and 7d demonstrated effective inhibitory profiles with Ki values of 20.3 ± 0.9 μM and 20.2 ± 0.9 μM, respectively. Kinetic inhibition assays showed non-competitive inhibition of AChE by the tested compounds. According to our docking studies, the most active compounds from both series (Families I and II) showed a binding mode similar to donepezil and interact with the same residues.

Keywords: Alzheimer's disease; benzoxazinones; human acetylcholinesterase inhibition; indole.

Publication types

  • Comparative Study

MeSH terms

  • Acetylcholinesterase / drug effects*
  • Acetylcholinesterase / metabolism
  • Alzheimer Disease / drug therapy
  • Benzoxazines / chemical synthesis
  • Benzoxazines / chemistry
  • Benzoxazines / pharmacology*
  • Cholinesterase Inhibitors / chemical synthesis
  • Cholinesterase Inhibitors / chemistry
  • Cholinesterase Inhibitors / pharmacology*
  • Donepezil
  • Drug Design
  • Humans
  • Indans / pharmacology
  • Molecular Docking Simulation
  • Piperazines / chemical synthesis
  • Piperazines / chemistry
  • Piperazines / pharmacology*
  • Piperidines / pharmacology
  • Protein Binding
  • Structure-Activity Relationship

Substances

  • Benzoxazines
  • Cholinesterase Inhibitors
  • Indans
  • Piperazines
  • Piperidines
  • Donepezil
  • Acetylcholinesterase